The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis (Q40701941)

22 September 2017

0 references

The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis (English)

1 reference

22 September 2017

1 reference

Zheng-Sheng Yang

1

1 reference

22 September 2017

Ning-Ning Lin

series ordinal

2

1 reference

22 September 2017

Li Li

series ordinal

3

1 reference

22 September 2017

Yang Li

series ordinal

4

1 reference

22 September 2017

publication date

14 June 2016

1 reference

Clinical Reviews in Allergy & Immunology

22 September 2017

published in

1 reference

22 September 2017

volume

51

1 reference

22 September 2017

issue

2

1 reference

22 September 2017

page(s)

240-247

1 reference

Novel anti-inflammatory therapies for the treatment of atherosclerosis

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8560-9

Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both

21 January 2018

1 reference

12 December 2020

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

12 December 2020

Cardiovascular biomarkers in patients with psoriasis

1 reference

12 December 2020

Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis

1 reference

12 December 2020

Assessment of arterial stiffness and cardiovascular hemodynamics by oscillometric method in psoriasis patients with normal cardiac functions

1 reference

12 December 2020

Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist

1 reference

12 December 2020

10.1007/S12016-016-8560-9

Identifiers

DOI

1 reference

Dimensions Publication ID

22 September 2017

1041124160

0 references

1 reference